Kyung Mi Han

Title: The Innovative Contributions of Kyung Mi Han

Introduction

Kyung Mi Han is a notable inventor based in Yongin, South Korea. He has made significant strides in the field of biotechnology, particularly in the development of therapeutic antibodies for cancer treatment. His work exemplifies the intersection of innovation and healthcare, aiming to improve patient outcomes through advanced medical solutions.

Latest Patents

Kyung Mi Han holds a patent for an "Anti-VEGF antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases." This novel anti-vascular endothelial growth factor (VEGF) antibody demonstrates a strong binding affinity for VEGF, which is crucial in inhibiting tumor growth. The antibody has shown remarkable binding properties to both human and mouse VEGF, effectively suppressing the proliferation and permeability of human umbilical vein endothelial cells (HUVEC). This innovation holds promise as a therapeutic option for cancer treatment.

Career Highlights

Throughout his career, Kyung Mi Han has been associated with prominent companies such as Dong-A Socio Holdings Co., Ltd. and Dong-A St Co., Ltd. His contributions to these organizations have been instrumental in advancing their research and development efforts in the pharmaceutical sector.

Collaborations

Kyung Mi Han has collaborated with esteemed colleagues, including Byong Moon Kim and Sung-Hee Lee. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries in the field of cancer treatment.

Conclusion

Kyung Mi Han's work in developing anti-VEGF antibodies represents a significant advancement in cancer therapy. His innovative approach and dedication to research continue to inspire progress in the medical field.